Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan
Status:
Completed
Trial end date:
2018-05-21
Target enrollment:
Participant gender:
Summary
This is a post-marketing surveillance study in Japan that will evaluate the safety and
patient satisfaction with GLASH VISTA™ (bimatoprost cutaneous solution 0.03%) in the
treatment of hypotrichosis of the eyelashes.